



Department of Vermont Health Access
 NOB 1 South, 280 State Drive
 Waterbury, Vermont 05671-1010

~Cystic Fibrosis ~

Prior Authorization Request Form

In order for members to receive Medicaid coverage for medications that require prior authorization, the prescriber must complete and fax this form to Change Healthcare. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information. For questions, please contact the Change Healthcare helpdesk at 1-844-679-5363.

Submit request via Fax: 1-844-679-5366

Prescribing physician:

Name: _____
 Physician NPI: _____
 Specialty: _____
 Phone#: _____
 Fax#: _____
 Address: _____
 Contact Person at Office: _____

Beneficiary:

Name: _____
 Medicaid ID#: _____
 Date of Birth: _____ Sex: _____
 Patient's Phone: _____
 Pharmacy Name: _____
 Pharmacy NPI: _____
 Pharmacy Phone: _____ Pharmacy Fax: _____

The following MUST be completed for MEDICAL BENEFIT requests:

HCPCS J-code or other code: _____
 Administering Provider/Facility: Name _____ NPI# _____ Medicaid ID# _____
 Patient Diagnosis: Cystic Fibrosis Other: _____

Mucolytics:

- Bronchitol® (mannitol) capsules for inhalation
 Inhale the contents of 10 capsules (400mg) twice daily
- Pulmozyme® (dornase alfa inhalation) 1 mg/ml, 2.5 ml ampules
 - Administer via nebulizer once daily Dispense# 30 Refill _____ times
 - Administer via nebulizer twice daily Dispense# 60 Refill _____ times

Inhaled Antibiotics:

Preferred Agents:

- Kitabis® (tobramycin) Solution: Administer via nebulizer twice daily, alternating 28 days on and 28 days off
- Tobramycin Solution for inhalation 300mg/5mL ampules: Administer via nebulizer twice daily, alternating 28 days on and 28 days off
- TOBI® (tobramycin) Podhaler 28 mg capsules (capsules for use with Podhaler only, requires prior trial of another form of inhaled tobramycin): Administer 4 capsules via Podhaler twice daily, alternating 28 days on and 28 days off

Non-preferred Agents (documentation must be submitted including reasons why the preferred products cannot be used):

- Bethkis®(tobramycin) Solution: Administer via nebulizer twice daily, alternating 28 days on and 28 days off
- Cayston® (aztreonam) Solution: Administer via nebulizer three times daily, alternating 28 days on and 28 days off
- TOBI® (tobramycin solution for inhalation) 300mg/5 mL ampules: Administer via nebulizer twice daily, alternating 28 days on and 28 days off
- Tobramycin Solution for inhalation 300mg/4mL ampules: Administer via nebulizer twice daily, alternating 28 days on and 28 days off





Department of Vermont Health Access
 NOB 1 South, 280 State Drive
 Waterbury, Vermont 05671-1010

CFTR Gene Mutation Potentiators:

Kalydeco® (ivacaftor) packets 50mg (less than 14kg) 75mg (greater than 14kg)

Kalydeco® (ivacaftor) 150mg tablets

Directions _____

Orkambi® (lumacaftor/ivacaftor) tablets 100/125mg 200/125mg

Orkambi® (lumacaftor/ivacaftor) Packets 100/125mg (less than 14kg) 150/188mg (greater than 14kg)

Directions _____

Symdeko® (Tezacaftor/Ivacaftor & Ivacaftor) 50/75mg 100/150mg

Directions _____

Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor & Ivacaftor) 50/25/37.5 and 75mg 100/50/75 and 150mg

Directions _____

By completing this form, I hereby certify that the above request is true, accurate and complete. That the request is medically necessary, does not exceed the medical needs of the member, and is clinically supported in the patient's medical records. I also understand that any misrepresentations or concealment of any information requested in the prior authorization request may subject me to audit and/or recoupment.

Prescriber's Signature: _____ **Date:** _____